1. Front Behav Neurosci. 2015 Oct 20;9:267. doi: 10.3389/fnbeh.2015.00267. 
eCollection 2015.

Pharmacological correction of excitation/inhibition imbalance in Down syndrome 
mouse models.

Souchet B(1), Guedj F(2), Penke-Verdier Z(3), Daubigney F(1), Duchon A(4), 
Herault Y(4), Bizot JC(5), Janel N(1), Créau N(1), Delatour B(3), Delabar JM(6).

Author information:
(1)Université Paris Diderot, Sorbonne Paris Cité, Adaptive Functional Biology, 
UMR Centre National de la Recherche Scientifique 8251 Paris, France.
(2)Université Paris Diderot, Sorbonne Paris Cité, Adaptive Functional Biology, 
UMR Centre National de la Recherche Scientifique 8251 Paris, France ; Tufts 
Medical Center, Mother Infant Research Institute Boston, MA, USA.
(3)Université Pierre-et-Marie-Curie Paris, 06 UMR S 1127, Centre National de la 
Recherche Scientifique UMR 7225, Institut National de la Santé et de la 
Recherche Médicale, U 1127, Sorbonne Universités, Institut du Cerveau et de la 
Moelle Epiniere Paris, France.
(4)Institut Génétique Biologie Moléculaire Cellulaire, Centre National de la 
Recherche Scientifique, Institut National de la Santé et de la Recherche 
Médicale, UMR7104, UMR964 Illkirch, France.
(5)Key-Obs Orléans, France.
(6)Université Paris Diderot, Sorbonne Paris Cité, Adaptive Functional Biology, 
UMR Centre National de la Recherche Scientifique 8251 Paris, France ; Université 
Pierre-et-Marie-Curie Paris, 06 UMR S 1127, Centre National de la Recherche 
Scientifique UMR 7225, Institut National de la Santé et de la Recherche 
Médicale, U 1127, Sorbonne Universités, Institut du Cerveau et de la Moelle 
Epiniere Paris, France.

Cognitive impairment in Down syndrome (DS) has been linked to increased synaptic 
inhibition. The underlying mechanisms remain unknown, but memory deficits are 
rescued in DS mouse models by drugs targeting GABA receptors. Similarly, 
administration of epigallocatechin gallate (EGCG)-containing extracts rescues 
cognitive phenotypes in Ts65Dn mice, potentially through GABA pathway. Some 
developmental and cognitive alterations have been traced to increased expression 
of the serine-threonine kinase DYRK1A on Hsa21. To better understand 
excitation/inhibition balance in DS, we investigated the consequences of 
long-term (1-month) treatment with EGCG-containing extracts in adult 
mBACtgDyrk1a mice that overexpress Dyrk1a. Administration of POL60 rescued 
components of GABAergic and glutamatergic pathways in cortex and hippocampus but 
not cerebellum. An intermediate dose (60 mg/kg) of decaffeinated green tea 
extract (MGTE) acted on components of both GABAergic and glutamatergic pathways 
and rescued behavioral deficits as demonstrated on the alternating paradigm, but 
did not rescue protein level of GABA-synthesizing GAD67. These results indicate 
that excessive synaptic inhibition in people with DS may be attributable, in 
large part, to increased DYRK1A dosage. Thus, controlling the level of active 
DYRK1A is a clear issue for DS therapy. This study also defines a panel of 
synaptic markers for further characterization of DS treatments in murine models.

DOI: 10.3389/fnbeh.2015.00267
PMCID: PMC4611057
PMID: 26539088